Sign in
Taking peoplePhase 1/2

Dual-target iTBS for Youth With ADHD

Key facts

Who runs it
Shanghai Mental Health Center
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 1/2
People taking part
15 people, planned
Started
1 Jan 2025
Expected to end
30 Dec 2026
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • TMS
Record updated
24 July 2025

Who can take part

Age
10 years to 18 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • ADHD Diagnosis: Meets the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
  • Inadequate Response to Medication: After a full course of pharmacological treatment, the SNAP-IV Parent Rating Scale (first 18 items, assessing inattention/hyperactivity-impulsivity) score >1, and the Clinical Global Impression-Severity Scale (CGI-S) score >2
  • Age and Gender: 10-18 years old; males or females
  • Intellectual Functioning: Full-scale intelligence quotient (IQ) >70 on the China-Wechsler Intelligence Scale for Children (C-WISC) (excluding participants with intellectual disability)
  • Symptom Severity: A score of ≥1.6 on either the Inattention or Hyperactivity/Impulsivity subscale of the SNAP-IV Parent Rating Scale
  • Medication Requirements:
  • Medication-naïve or currently off medication; 2) If currently on medication, must be on a stable medication regimen for at least 4 weeks prior to the baseline visit and throughout the study duration; 3) Prohibited medications: Psychostimulants; 7. Right-handed

Who cannot take part

  • Contraindications for MRI include metal implants in the body, claustrophobia, and tattoos
  • Currently receiving any non-medical treatments, such as cognitive behavioral therapy (CBT), neurofeedback, etc
  • Contraindications for TMS therapy include epilepsy, cardiac pacemakers, cochlear implants, and metal implants
  • Significant medical history: history of epilepsy, organic brain disorders, traumatic brain injury (TBI), or severe physical illnesses
  • Behavioral risks: history of violent or suicidal behavior
  • Comorbid neurodevelopmental disorders, such as autism spectrum disorder (ASD), tic disorders, etc
  • Comorbid psychiatric disorders: any other primary psychiatric disorders, except conduct disorder/oppositional defiant disorder, mild anxiety, or depression
  • Substance abuse
  • Female participants must not be pregnant or breastfeeding

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 10 and 18 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study will employ accelerated intermittent theta burst stimulation (aiTBS) targeting two transcranial magnetic stimulation (TMS) sites: the right inferior frontal gyrus and left inferior parietal lobule.

The 3 groups in the trial

  • Phase 1: Open-label dual-target aiTBSTreatment being tested

    Phase 1: Open label, single arm study to determine the preliminary efficacy, safety, and acceptability of aiTBS for youth with ADHD.

    Treatment: TMS

  • Phase 2: RCT design active aiTBSExisting treatment, for comparison

    Phase 1: A randomized, double-masked, controlled trial that will rigorously validate the efficacy and safety of dual-target aiTBS for youth with ADHD.

    Treatment: TMS

  • Phase 2: RCT design sham aiTBSSham treatment, for comparison

    Phase 2: A randomized, double-masked, controlled trial that will rigorously validate the efficacy and safety of dual-target aiTBS for youth with ADHD.

    Treatment: TMS

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Efficacy of Dual-target iTBS in Youth With Attention-Deficit/Hyperactivity Disorder (ADHD)
Fit questions
Built from NCT07084649, who can take part
Record updated
24 July 2025